Interferon Gamma 13-CA-Repeat Homozygous Genotype and a Low Proportion of CD4+ Lymphocytes Are Independent Risk Factors for Cytomegalovirus Reactivation with a High Number of Copies in Hematopoietic Stem Cell Transplantation Recipients

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 10, 2009, Pages 1296-1305

  Jaskula, Emilia ^a   Dlubek, Dorota ^a,b   Duda, Dorota ^b   Bogunia Kubik, Katarzyna ^a   Mlynarczewska, Anna ^a   Lange, Andrzej ^a,b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b Lower Silesian Center for Cellular Transplantation with National Bone Marrow Donor Registry   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GANCICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; INFECTION RISK; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; OVERALL SURVIVAL; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; COMMON VARIABLE IMMUNODEFICIENCY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DINUCLEOTIDE REPEATS; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-GAMMA; INTRONS; MALE; POLYMORPHISM, GENETIC; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 69749084392     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.06.008     Document Type: Article

References (57)

1. Bego M.G., and St Jeor S. Human cytomegalovirus infection of cells of hematopoietic origin: HCMV-induced immunosuppression, immune evasion, and latency. Exp Hematol 34 (2006) 555-570
2. Fraser G.A., Walker II, Canadian B., and Marrow Transplant G. Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations. Biol Blood Marrow Transplant 10 (2004) 287-297
3. + T cells via a cytokine relay network. J Immunol 180 (2008) 6923-6932
4. Schoenborn J.R., and Wilson C.B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96 (2007) 41-101
5. Petrovsky N., and Harrison L.C. HLA class II-associated polymorphism of interferon-γ production implications for HLA-disease association. Hum Immunol 53 (1997) 12-16
6. Lange A. Genetic factors predicting IFN-gamma generation potential in patients with sarcoidosis and after haematopoietic stem cell transplantation. Int J Immunogenet 35 (2008) 385-388
7. Pravica V., Perrey C., Stevens A., et al. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol 61 (2000) 863-866
8. Pravica V., Asderakis A., Perrey C., et al. In vitro production of interferon-gamma correlates with CA repeat polymorphism in the human IFN-GAMMA gene. Eur J Immunogenet 26 (1999) 1-3
9. Miyake K., Nakashima H., Akahoshi M., et al. Genetically determined interferon-gamma production influences the histological phenotype of lupus nephritis. Rheumatology (Oxford) 41 (2002) 518-524
10. Lee J.Y., Goldman D., Piliero L.M., et al. Interferon-gamma polymorphisms in systemic lupus erythematosus. Genes Immunol 2 (2001) 254-257
11. Saha A., Dhir A., Ranjan A., et al. Functional IFNG polymorphism in intron 1 in association with an increased risk to promote sporadic breast cancer. Immunogenetics 57 (2005) 165-171
12. Apperley J., Carreras E., Gluckman E., et al. Haematopoietic Stem Cell Transplantation-ESH/EBMT Handbook. 5th ed (2008), Forum Service Editore, Genoa, Italy 592
13. Mlynarczewska A., Wysoczanska B., Karabon L., et al. Lack of IFN-gamma 2/2 homozygous genotype independently of recipient age and intensity of conditioning regimen influences the risk of aGVHD manifestation after HLA-matched sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 34 (2004) 339-344
14. Machida U., Kami M., Fukui T., et al. Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation. J Clin Microbiol 38 (2000) 2536-2542
15. Gandhi M.K., and Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4 (2004) 725-738
16. Mohty M., Jacot W., Faucher C., et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 17 (2003) 2168-2177
17. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-lH in delaying immune reconstitution. Blood 99 (2002) 4357-4363
18. Bjorklund A., Aschan J., Labopin M., et al. Bone marrow risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Transplantation 40 (2007) 1055-1062
19. Kim D.H., Kim J.G., Lee N.Y., et al. Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection. Bone Marrow Transplant 34 (2004) 21-27
20. Ljungman P., de La Camara R., Milpied N., et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 99 (2002) 3050-3056
21. Cortez K.J., Fischer S.H., Fahle G.A., et al. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis 188 (2003) 967-972
22. Schulenburg A., Watkins-Riedel T., Greinix H.A.T., et al. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR. Bone Marrow Transplant 28 (2001) 765-768
23. Busca A., de Fabritiis P., Ghisetti V., et al. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post-allogeneic stem cell transplantation. Transpl Infect Dis 9 (2007) 102-107
24. Hakki M., Riddell S.R., Storek J., et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 102 (2003) 3060-3067
25. Almyroudis N.G., Jakubowski A., Jaffe D., et al. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 9 (2007) 286-294
26. Harari A., Zimmerli S.C., and Pantaleo G. Cytomegalovirus (CMV)-specific cellular immune responses. Hum Immunol 65 (2004) 500-506
27. Razonable R.R., Brown R.A., Wilson J., et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 73 (2002) 968-973
28. Mengelle C., Sandres-Sauné K., Pasquier C., et al. Automated extraction and quantification of human cytomegalovirus DNA in whole blood by real-time PCR assay. J Clin Microbiol 41 (2003) 3840-3845
29. Boivin G., Handfield J., Toma E., et al. Comparative evaluation of the cytomegalovirus DNA load in polymorphonuclear leukocytes and plasma of human immunodeficiency virus-infected subjects. J Infect Dis 178 (1998) 1544-1546
30. Ouyang Q., Wagner W.M., Wikby A., et al. Compromised interferon gamma (IFN-gamma) production in the elderly to both acute and latent viral antigen stimulation: contribution to the immune risk phenotype?. Eur Cytokine Netw 13 (2002) 392-394
31. Avetisyan G., Larsson K., Aschan J., et al. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant 38 (2006) 687-692
32. Brandt B., Meyer-Staeckling S., Schmidt H., et al. Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. Clin Cancer Res 12 (2006) 7252-7260
33. Suzuki M., Kageyama S., Shinmura K., et al. Inverse relationship between the length of the EGFR CA repeat polymorphism in lung carcinoma and protein expression of EGFR in the carcinoma. J Surg Oncol 98 (2008) 457-461
34. Beilin J., Ball E.M., Favaloro J.M., et al. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol 25 (2000) 85-96
35. Agarwal A.K., Giacchetti G., Lavery G., et al. CA-repeat polymorphism in intron 1 of HSD11B2: effects on gene expression and salt sensitivity. Hypertension 36 (2000) 187-194
36. González A.A., Carvajal C.A., Riquelme E., et al. A polymorphic GT short tandem repeat affecting beta-ENaC mRNA expression is associated with low-renin essential hypertension. Am J Hypertens 20 (2007) 800-806
37. Seitzer U., Swider C., Stüber F., et al. Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine 9 (1997) 787-790
38. Wilson A.G., Symons J.A., McDowell T.L., et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. USA 94 (1997) 3195-3199
39. Wilson A.G., de Vries N., Pociot F., et al. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177 (1993) 557-560
40. Wysoczanska B., Bogunia-Kubik K., Suchnicki K., et al. Combined association between IFN-gamma 3,3 homozygosity and DRB1*03 in Löfgren's syndrome patients. Immunol Lett 91 (2004) 127-131
41. Swider C., Laba A., Moniewska A., et al. Presence of mRNA for interferon-gamma (IFN-gamma) in blood mononuclear cells is associated with an active stage I sarcoidosis. Clin Exp Immunol 100 (1995) 401-405
42. Bogunia-Kubik K., Mlynarczewska A., Wysoczanska B., et al. Recipient interferon-gamma 3/3 genotype contributes to the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica 90 (2005) 425-426
43. Puliaev R., Nguyen P., Finkelman F.D., et al. Differential requirement for IFN-gamma in CTL maturation in acute murine graft-versus-host disease. J Immunol 173 (2004) 910-919
44. Bogunia-Kubik K., Mlynarczewska A., Jaskula E., et al. The presence of IFNG 3/3 genotype in the recipient associates with increased risk for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 132 (2006) 326-332
45. Abbott W., Gane E., Winship I., et al. Polymorphism in intron 1 of the interferon-gamma gene influences both serum immunoglobulin E levels and the risk for chronic hepatitis B virus infection in Polynesians. Immunogenetics 59 (2007) 187-195
46. Cavet J., Dickinson A.M., Norden J., et al. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 98 (2001) 1594-1600
47. Karabon L., Wysoczanska B., Bogunia-Kubik K., et al. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease. Hum Immunol 66 (2005) 700-710
48. Noori-Daloii M.R., Rashidi-Nezhad A., Izadi P., et al. Transforming growth factor-beta1 codon 10 polymorphism is associated with acute GVHD after allogenic BMT in Iranian population. Ann Transplant 12 (2007) 5-10
49. Bogunia-Kubik K., Wysoczanska B., and Lange A. Non-HLA gene polymorphisms and the outcome of allogeneic hemato-poietic stem cell transplantation. Curr Stem Cell Res Ther 1 (2006) 239-253
50. Viel D.O., Tsuneto L.T., Sossai C.R., et al. IL-2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Scand J Immunol 66 (2007) 703-710
51. Craddock C., Szydlo R.M., Dazzi F., et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol 112 (2001) 228-236
52. Ljungman P., Brand R., Einsele H., et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 102 (2003) 4255-4260
53. Ljungman P. Risk assessment in haematopoietic stem cell transplantation: viral status. Best Pract Res Clin Haematol 20 (2007) 209-217
54. Zhou W., Longmate J., Lacey S.F., et al. Impact of donor CMV status on viral infection and reconstitution of multi-function CMV-specific T-cells in CMV-positive transplant recipients. Blood 113 (2009) 6465-6476
55. Fisher R.A. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. Transpl Infect Dis 11 (2009) 195-202
56. Miller-Kittrell M., and Sparer T.E. Feeling manipulated: cytomegalovirus immune manipulation. Virol J 6 (2009) 4
57. Mocarski Jr. E.S. Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell Microbiol 6 (2004) 707-717